Plain-English translation of NCT07001956 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new injectable medication called UTAA91 for people whose rheumatoid arthritis (RA) has not improved with standard treatments. The main goal is to see whether this new treatment is safe to use. You would be one of about 24 people in this early-stage study.
Rheumatoid arthritis can be difficult to control with existing medications, leaving some patients with ongoing pain and joint damage. Researchers are testing this new treatment to find additional options for people who haven't responded well to standard therapies.
You likely qualify if…
You likely don't qualify if…
You would receive the as part of this trial. The study will monitor your safety closely, which means you'll have regular check-ups and tests to make sure the treatment is working well and not causing harmful side effects. Since this is an early-stage study with a small group of patients, the researchers will be watching you carefully to understand how your body responds to this new treatment.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enrollment target
~24 participants
Started
May 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiubai Li, MD
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.